Schroder Investment Management Group Trims Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Schroder Investment Management Group lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 50.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,230 shares of the biopharmaceutical company's stock after selling 24,112 shares during the period. Schroder Investment Management Group's holdings in Alnylam Pharmaceuticals were worth $5,483,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the business. Regeneron Pharmaceuticals Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $1,045,822,000. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth $577,941,000. Raymond James Financial Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $65,295,000. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $61,160,000. Finally, Proficio Capital Partners LLC increased its position in Alnylam Pharmaceuticals by 25,929.6% during the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock worth $45,570,000 after purchasing an additional 192,916 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded down $6.36 during trading on Tuesday, hitting $226.59. The company had a trading volume of 448,888 shares, compared to its average volume of 846,032. The stock has a 50 day simple moving average of $258.16 and a 200 day simple moving average of $259.83. The firm has a market capitalization of $29.48 billion, a P/E ratio of -104.47 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Remove Ads

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. StockNews.com lowered shares of Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Scotiabank upped their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research report on Monday, March 31st. HC Wainwright restated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Finally, Chardan Capital restated a "buy" rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $316.25.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,548 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 over the last 90 days. 1.50% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.